In a significant blow to healthcare integrity in the Pacific Northwest, the owner and operator of an Oregon-based diagnostic testing group has officially admitted to orchestrating a sophisticated, multi-year scheme to defraud federal healthcare programs and private insurance providers. Mehrdad Gerami, 67, the principal figure behind Coastal Diagnostic Testing Group, entered a guilty plea to conspiracy to commit healthcare fraud, bringing to light a calculated operation that resulted in an estimated financial loss exceeding $2.1 million.
The case, which spanned several years and involved multiple locations across rural and coastal Oregon, highlights the persistent vulnerabilities within the billing processes of specialized diagnostic services. As the judicial process moves toward sentencing, the fallout from this case serves as a stark reminder of the rigorous oversight federal agencies are now applying to diagnostic providers.
Main Facts: The Anatomy of the Fraud
At the heart of the litigation is the systematic manipulation of billing codes by Coastal Diagnostic Testing Group, a network with operations spanning Coos Bay, Brookings, Reedsport, Florence, and Roseburg. Gerami, who exercised total operational control over the company, directed a scheme that prioritized revenue generation over clinical accuracy.
The fraudulent activities primarily centered on "upcoding"—the practice of billing for a higher level of service than what was actually performed. Specifically, Coastal Diagnostic regularly submitted claims to the U.S. Department of Health and Human Services (HHS), the Veterans Health Administration (VHA), and private insurance carriers for intensive, in-office sleep studies. In reality, the patients involved had only undergone significantly less expensive and less intensive at-home sleep studies. By inflating the complexity of the service, Gerami was able to capture the difference in reimbursement rates, a discrepancy that compounded into millions of dollars in illicit gains.
Beyond upcoding, the investigation uncovered a more brazen form of deception: "phantom billing." During periods of low patient volume or when specific diagnostic centers were underperforming, Gerami allegedly directed his staff to fabricate claims entirely. By utilizing the personal health information of existing patients, the company billed for sleep studies that never took place. These fraudulent entries were designed to mask revenue shortfalls and artificially inflate the company’s financial performance.
Chronology: A Multi-Year Pattern of Deceit
The timeline of the illegal activity, as outlined in court documents provided by the U.S. Attorney’s Office, spans from 2021 through early 2026.
- 2021–2022 (The Incubation Phase): Investigators believe the fraudulent billing patterns began to solidify during this period. As Coastal Diagnostic expanded its footprint across southern Oregon, the pressure to meet financial benchmarks grew, leading to the initial implementation of the upcoding scheme.
- 2023–2025 (Operational Escalation): As the scheme matured, internal records suggest that the falsification of records became a standard business practice. Employees were not merely incidental to the process; according to prosecutors, they were directed by Gerami to facilitate the billing of non-existent procedures to stabilize the company’s monthly revenue.
- June 22, 2026: Federal prosecutors officially charged Mehrdad Gerami by information, marking the end of the investigative phase and the start of formal judicial proceedings.
- Post-Charge Proceedings: Following the filing of charges, Gerami entered into a plea agreement, acknowledging the depth of the conspiracy and his role as the primary architect.
- January 26, 2027: The scheduled date for sentencing, where a U.S. District Court judge will determine the final penalties for the defendant.
Supporting Data: The Scope of the Loss
The financial impact of the fraud is both substantial and well-documented. According to the final forensic accounting, the total loss attributed to the fraudulent activity stands at exactly $2,124,363.41.
This figure represents more than just a balance sheet error; it reflects a direct depletion of resources intended for legitimate medical care. The losses were distributed across:
- Federal Healthcare Programs: HHS and the Veterans Health Administration were primary targets. The exploitation of the VHA is particularly notable, as it represents a diversion of funds specifically allocated to the health and well-being of military veterans.
- Private Insurers: A significant portion of the loss involves private entities, which, while capable of absorbing initial costs, ultimately pass these losses on to employers and individuals through increased premiums.
As part of his plea agreement, Gerami has committed to full restitution. The process of recovering these funds will be a priority for the court, ensuring that the victims—both public agencies and private companies—are compensated for the financial damage incurred.
Official Responses and Prosecution
The investigation was a collaborative effort between the Health and Human Services Office of Inspector General (HHS-OIG) and the Department of Veterans Affairs Office of Inspector General (VA-OIG). These agencies possess specialized units dedicated to auditing healthcare providers and identifying anomalous billing patterns.
"Healthcare fraud is not a victimless crime," noted an official familiar with the investigation. "It undermines the trust inherent in the patient-provider relationship and threatens the sustainability of programs designed to help those in need."
The case is currently being prosecuted by Assistant U.S. Attorneys Joseph Huynh and Julia Jarrett. Their work has been instrumental in dismantling the Coastal Diagnostic operation and securing the defendant’s admission of guilt. The sentencing hearing in January 2027 will be the culmination of their efforts, with Gerami facing a maximum of 10 years in federal prison, a $250,000 fine, and three years of supervised release.
Implications: The Future of Diagnostic Oversight
The case of Coastal Diagnostic Testing Group serves as a microcosm of the broader challenges facing the healthcare industry. As sleep studies become increasingly common—driven by a growing awareness of conditions like obstructive sleep apnea—the volume of claims processed by insurers has skyrocketed. This volume can often mask individual instances of fraud.
The Rise of Data Analytics in Fraud Detection
This conviction underscores the increasing efficacy of data analytics in identifying medical fraud. Federal agencies now employ sophisticated software that compares billing patterns across regions. If a single clinic in Oregon is billing for in-office sleep studies at a rate significantly higher than the national or state average, it triggers an audit. The sheer volume of Coastal Diagnostic’s "in-office" claims compared to the physical limitations of their facilities likely served as a primary red flag.
The Impact on Rural Healthcare
The geographic focus of this crime—coastal and rural Oregon—adds a layer of complexity. Patients in these regions often have fewer choices for diagnostic testing. When a provider exploits this trust, it not only impacts the insurers but also potentially disrupts the continuity of care for residents who may rely solely on these facilities for their medical needs.
Future Regulatory Vigilance
In the wake of this case, industry experts anticipate a tightening of requirements for diagnostic testing groups. This may include:
- Increased Auditing: More frequent site visits and retrospective reviews of billing codes for smaller, independent diagnostic labs.
- Enhanced Documentation Requirements: Stricter mandates for proof-of-service, such as requiring digital time-stamping for in-office procedures.
- Whistleblower Incentives: Encouraging employees—who, as noted in the court documents, were often directed by Gerami to participate in the fraud—to report illicit practices earlier.
As the legal proceedings draw to a close, the focus shifts to how the healthcare community will respond. For providers, the case serves as a warning that federal authorities are increasingly capable of peeling back the layers of complex billing schemes. For insurers and federal programs, the challenge remains to balance the accessibility of care with the rigorous verification of the services provided.
Ultimately, the sentencing of Mehrdad Gerami will be a pivotal moment, signaling that while the wheels of justice may turn slowly, the commitment to protecting the integrity of the American healthcare system remains a high priority for federal prosecutors. The $2.1 million recovery, while significant, is only one component of the restitution; the long-term task of rebuilding confidence in the diagnostic testing sector in Oregon remains an ongoing challenge for the industry.
